Multi-epitope Models Explain How Pre-existing Antibodies Affect the Generation of Broadly Protective Responses to Influenza

PLoS Pathogens

Volumn 12, Issue 6, 2016, Pages

  Zarnitsyna, Veronika I ^a   Lavine, Jennie ^b   Ellebedy, Ali ^a,b   Ahmed, Rafi ^a,b   Antia, Rustom ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HEMAGGLUTININ; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS ANTIBODY;

ARTICLE; B LYMPHOCYTE ACTIVATION; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CELL STIMULATION; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; INFLUENZA A (H1N1); INFLUENZA A (H5N1); PANDEMIC INFLUENZA; PUBLIC HEALTH; SEASONAL INFLUENZA; VACCINATION; ANIMAL; HUMORAL IMMUNITY; IMMUNOLOGY; INFLUENZA; ORTHOMYXOVIRUS INFECTION; THEORETICAL MODEL;

ANIMALS; ANTIBODIES, VIRAL; EPITOPES, B-LYMPHOCYTE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNITY, HUMORAL; INFLUENZA VACCINES; INFLUENZA, HUMAN; MODELS, THEORETICAL; ORTHOMYXOVIRIDAE INFECTIONS;

EID: 84978818201     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005692     Document Type: Article

References (50)

1. Molinari NAM, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007Jun;25(27):5086–96. 17544181
2. Yewdell J, García-Sastre A, Influenza virus still surprises. Curr Opin Microbiol. 2002Aug;5(4):414–8. 12160862
3. Basta NE, Halloran ME, Matrajt L, Longini IM, JrEstimating influenza vaccine efficacy from challenge and community-based study data. Am J Epidemiol. 2008Dec;168(12):1343–52. doi: 10.1093/aje/kwn25918974084
4. Basta NE, Chao DL, Halloran ME, Matrajt L, Longini IM, JrStrategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States. Am J Epidemiol. 2009Sep;170(6):679–86. doi: 10.1093/aje/kwp23719679750
5. Osterholm MT, Kelley NS, Sommer A, Belongia EA, Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012Jan;12(1):36–44. 22032844
6. Kelly H, Valenciano M, Estimating the effect of influenza vaccines. Lancet Infect Dis. 2012Jan;12(1):5–6. 22032845
7. Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA, Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis. 2007Oct;7(10):658–66. 17897608
8. Grebe KM, Yewdell JW, Bennink JR, Heterosubtypic immunity to influenza A virus: where do we stand?Microbes Infect. 2008Jul;10(9):1024–9. doi: 10.1016/j.micinf.2008.07.00218662798
9. Wrigley NG, Electron microscopy of influenza virus. Br Med Bull. 1979Jan;35(1):35–8. 367484
10. Taylor HP, Armstrong SJ, Dimmock NJ, Quantitative relationships between an influenza virus and neutralizing antibody. Virology. 1987Aug;159(2):288–98. 3617501
11. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y, Evolution and ecology of influenza A viruses. Microbiol Rev. 1992Mar;56(1):152–79. 1579108
12. Bouvier NM, Palese P, The biology of influenza viruses. Vaccine. 2008Sep;26Suppl 4:D49–53. 19230160
13. Wei CJ, Boyington JC, McTamney PM, Kong WP, Pearce MB, Xu L, et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science. 2010Aug;329(5995):1060–4. 20647428
14. Kanekiyo M, Wei CJ, Yassine HM, McTamney PM, Boyington JC, Whittle JRR, et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature. 2013Jul;499(7456):102–6. 23698367
15. Krammer F, Pica N, Hai R, Margine I, Palese P, Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol. 2013Jun;87(12):6542–50. doi: 10.1128/JVI.00641-1323576508
16. Margine I, Krammer F, Hai R, Heaton NS, Tan GS, Andrews SA, et al. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J Virol. 2013Oct;87(19):10435–46. doi: 10.1128/JVI.01715-1323903831
17. Krammer F, Margine I, Hai R, Flood A, Hirsh A, Tsvetnitsky V, et al. H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge. J Virol. 2014Feb;88(4):2340–3. doi: 10.1128/JVI.03183-1324307585
18. Impagliazzo A, Milder F, Kuipers H, Wagner MV, Zhu X, Hoffman RMB, et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science. 2015Sep;349(6254):1301–6. 26303961
19. Yassine HM, Boyington JC, McTamney PM, Wei CJ, Kanekiyo M, Kong WP, et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med. 2015Sep;21(9):1065–70. 26301691
20. Ellebedy AH, Krammer F, Li GM, Miller MS, Chiu C, Wrammert J, et al. Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proc Natl Acad Sci U S A. 2014Sep;111(36):13133–8. doi: 10.1073/pnas.141407011125157133
21. Nimmerjahn F, Ravetch JV, Antibody-mediated modulation of immune responses. Immunol Rev. 2010Jul;236:265–75. 20636822
22. Hilborn R, Mangel M, The ecological detective: confronting models with data. Monographs in population biology 28. Princeton, N.J.: Princeton University Press; 1997.
23. Ndifon W, Wingreen NS, Levin SA, Differential neutralization efficiency of hemagglutinin epitopes, antibody interference, and the design of influenza vaccines. Proc Natl Acad Sci U S A. 2009May;106(21):8701–6. doi: 10.1073/pnas.090342710619439657
24. Taylor HP, Dimmock NJ, Competitive binding of neutralizing monoclonal and polyclonal IgG to the HA of influenza A virions in solution: only one IgG molecule is bound per HA trimer regardless of the specificity of the competitor. Virology. 1994Nov;205(1):360–3. 7975232
25. Corti D, Suguitan AL, JrPinna D, Silacci C, Fernandez-Rodriguez BM, Vanzetta F, et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest. 2010May;120(5):1663–73. doi: 10.1172/JCI4190220389023
26. Zarnitsyna VI, Ellebedy AH, Davis C, Jacob J, Ahmed R, Antia R, Masking of antigenic epitopes by antibodies shapes the humoral immune response to influenza. Philos Trans R Soc Lond B Biol Sci. 2015Sep;370 (1676). doi: 10.1098/rstb.2014.024826194761
27. Nara PL, Tobin GJ, Chaudhuri AR, Trujillo JD, Lin G, Cho MW, et al. How can vaccines against influenza and other viral diseases be made more effective?PLoS Biol. 2010;8(12):e1000571. doi: 10.1371/journal.pbio.100057121203586
28. Andrews SF, Huang Y, Kaur K, Popova LI, Ho IY, Pauli NT, et al. Immune history profoundly affects broadly protective B cell responses to influenza. Sci Transl Med. 2015Dec;7(316):316ra192. doi: 10.1126/scitranslmed.aad052226631631
29. Chen J, Wharton SA, Weissenhorn W, Calder LJ, Hughson FM, Skehel JJ, et al. A soluble domain of the membrane-anchoring chain of influenza virus hemagglutinin (HA2) folds in Escherichia coli into the low-pH-induced conformation. Proc Natl Acad Sci U S A. 1995Dec;92(26):12205–9. 8618870
30. Bommakanti G, Citron MP, Hepler RW, Callahan C, Heidecker GJ, Najar TA, et al. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc Natl Acad Sci U S A. 2010Aug;107(31):13701–6. doi: 10.1073/pnas.100746510720615991
31. Kleinstein SH, Singh JP, Toward quantitative simulation of germinal center dynamics: biological and modeling insights from experimental validation. J Theor Biol. 2001Aug;211(3):253–75. 11444956
32. Oprea M, Perelson AS, Exploring the mechanisms of primary antibody responses to T cell-dependent antigens. Journal of Theoretical Biology. 1996;181:215–236. 8869124
33. Zhang Y, Meyer-Hermann M, George LA, Figge MT, Khan M, Goodall M, et al. Germinal center B cells govern their own fate via antibody feedback. J Exp Med. 2013Mar;210(3):457–64. doi: 10.1084/jem.2012015023420879
34. Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS, Kinetics of influenza A virus infection in humans. J Virol. 2006;80(15):7590–9. doi: 10.1128/JVI.01623-0516840338
35. Saenz RA, Quinlivan M, Elton D, Macrae S, Blunden AS, Mumford JA, et al. Dynamics of influenza virus infection and pathology. J Virol. 2010Apr;84(8):3974–83. doi: 10.1128/JVI.02078-0920130053
36. Qiao L, Phipps-Yonas H, Hartmann B, Moran TM, Sealfon SC, Hayot F, Immune response modeling of interferon beta-pretreated influenza virus-infected human dendritic cells. Biophys J. 2010Feb;98(4):505–14. 20159146
37. Pawelek KA, Huynh GT, Quinlivan M, Cullinane A, Rong L, Perelson AS, Modeling within-host dynamics of influenza virus infection including immune responses. PLoS Comput Biol. 2012;8(6):e1002588. doi: 10.1371/journal.pcbi.100258822761567
38. Fribourg M, Hartmann B, Schmolke M, Marjanovic N, Albrecht RA, García-Sastre A, et al. Model of influenza A virus infection: dynamics of viral antagonism and innate immune response. J Theor Biol. 2014Jun;351:47–57. doi: 10.1016/j.jtbi.2014.02.02924594370
39. Lee HY, Topham DJ, Park SY, Hollenbaugh J, Treanor J, Mosmann TR, et al. Simulation and prediction of the adaptive immune response to influenza A virus infection. J Virol. 2009Jul;83(14):7151–65. doi: 10.1128/JVI.00098-0919439465
40. Miao H, Hollenbaugh JA, Zand MS, Holden-Wiltse J, Mosmann TR, Perelson AS, et al. Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus. J Virol. 2010Jul;84(13):6687–98. doi: 10.1128/JVI.00266-1020410284
41. Wu H, Kumar A, Miao H, Holden-Wiltse J, Mosmann TR, Livingstone AM, et al. Modeling of influenza-specific CD8+ T cells during the primary response indicates that the spleen is a major source of effectors. J Immunol. 2011Nov;187(9):4474–82. 21948988
42. Francis T, JrThe current status of the control of influenza. Ann Intern Med. 1955Sep;43(3):534–8. 13249235
43. Francis T, On the doctrine of original antigenic sin. American Philosophical Society. 1960;p. 572–578.
44. Lessler J, Riley S, Read JM, Wang S, Zhu H, Smith GJD, et al. Evidence for antigenic seniority in influenza A (H3N2) antibody responses in southern China. PLoS Pathog. 2012;8(7):e1002802. 22829765
45. Fonville JM, Wilks SH, James SL, Fox A, Ventresca M, Aban M, et al. Antibody landscapes after influenza virus infection or vaccination. Science. 2014Nov;346(6212):996–1000. doi: 10.1126/science.125642725414313
46. Kucharski AJ, Lessler J, Read JM, Zhu H, Jiang CQ, Guan Y, et al. Estimating the Life Course of Influenza A(H3N2) Antibody Responses from Cross-Sectional Data. PLoS Biol. 2015Mar;13(3):e1002082. 25734701
47. Halloran ME, Longini IM, JrJ SC, Design and analysis of vaccine studies. ISBN 978-0-387-40313-7. Springer Science & Business Media; 2009.
48. Belshe RB, Frey SE, Graham I, Mulligan MJ, Edupuganti S, Jackson LA, et al. Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant. J Infect Dis. 2011Mar;203(5):666–73. doi: 10.1093/infdis/jiq09321282194
49. McKay MD, Beckman RJ, J CW, A Comparison of Three Methods for Selecting Values of Input Variables in the Analysis of Output from a Computer Code. Technometrics. 1979May;21(2):239–245.
50. Slifka MK, Antia R, Whitmire JK, Ahmed R, Humoral immunity due to long-lived plasma cells. Immunity. 1998Mar;8(3):363–72. 9529153